Frederick Raal to Clinical Trials, Phase II as Topic
This is a "connection" page, showing publications Frederick Raal has written about Clinical Trials, Phase II as Topic.
Connection Strength
0,285
-
Long-term Low-Density Lipoprotein Cholesterol-Lowering Efficacy, Persistence, and Safety of Evolocumab in Treatment of Hypercholesterolemia: Results Up to 4 Years From the Open-Label OSLER-1 Extension Study. JAMA Cardiol. 2017 06 01; 2(6):598-607.
Score: 0,143
-
Reduction of low-density lipoprotein cholesterol by monoclonal antibody inhibition of PCSK9. Annu Rev Med. 2014; 65:417-31.
Score: 0,113
-
Efficacy and safety of evolocumab (AMG 145), a fully human monoclonal antibody to PCSK9, in hyperlipidaemic patients on various background lipid therapies: pooled analysis of 1359 patients in four phase 2 trials. Eur Heart J. 2014 Sep 01; 35(33):2249-59.
Score: 0,029